PRPaula Rodríguez‐Marcos

Paula Rodríguez‐Marcos

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Paula Rodríguez‐Marcos has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Integrating patient-reported outcomes into explainable machine learning models for long-term survival prediction in TKI-treated metastatic renal cell carcinoma

    by Miguel Ángel Gómez-Luque, Guillermo Lendínez-Cano, Belén Carrero-García, Paula Rodríguez-Marcos, Carmen Belén Congregado-Ruiz, Rafael Antonio Medina-López

  • Clinical Variable‐Based Machine Learning for Predicting Early mCRPC Using Exclusively Clinical Variables: Development and Multicenter External Validation

    by Miguel Ángel Gómez‐Luque, Pedro De Pablos‐Rodríguez, Daniel Adolfo Pérez‐Fentes, Natalia Picola‐Brau, Arnau Abella‐Serra, María Elena Martínez‐Corral, Paula Rodríguez‐Marcos, Alicia López‐Abad, Marc Costa‐Planells, Sara Martínez‐Breijo, et al.

    Background and Objective: Metastatic hormone‐sensitive prostate cancer (mHSPC) exhibits heterogeneous progression patterns, with early progression to metastatic castration‐resistant prostate cancer (mCRPC) within 12 months indicating aggressive tumor biology and poor prognosis. Current risk stratification tools (CHAARTED, LATITUDE) offer limited individualized prediction. Machine learning approaches are increasingly applied to predict prostate cancer progression, but most models show modest performance (AUC 0.68–0.72), limited external validation, or require genomic variables unavailable in routine practice. This study aimed to develop and externally validate a novel RINH algorithm for predicting early mCRPC progression (≤ 12 months) using exclusively clinical variables, positioning it as a superior alternative to conventional ML classifiers. Methods: This multicenter study enrolled 412 patients with de novo mHSPC from seven Spanish academic centers using mixed retrospective‐prospective data collection. Twenty clinical variables were recorded, including demographics, PSA, ISUP grade, metastatic localization, CHAARTED/LATITUDE classifications, and treatment modalities. Following RINH‐based outlier exclusion (55 patients), 357 patients (29 with early progression, 8.1%) were used to train six ML algorithms: RINH, Logistic Regression, Linear Discriminant, Support Vector Machine, Random Forest, and Subspace Discriminant. A two‐tiered validation strategy integrated stratified fivefold cross‐validation across all centers and formal external validation using center 1 ( n = 121, 19 events) for training and centers 2–7 ( n = 207, 10 events) for independent testing. Performance metrics included AUC, sensitivity, specificity, accuracy, and F1‐score. Key Findings and Limitations: Artificial intelligence and machine learning (ML) are transforming oncology, promising personalized risk stratification beyond traditional clinical criteria. In metastatic hormone‐sensitive prostate cancer (mHSPC), early progression to castration resistance (mCRPC) within 12 months signals aggressive biology and poor prognosis, yet current tools (CHAARTED, LATITUDE) offer limited individualized prediction. Multiple ML models have been proposed with variable success: most achieve modest performance (AUC 0.68–0.72), lack robust external validation, or rely on genomic variables inaccessible in routine practice. We propose a novel approach using the Rivality Index Neighborhood (RINH) algorithm, demonstrating superior predictive capacity in an initial multicenter validation with exclusively clinical variables. This study provides rigorous multicenter external validation, advancing toward implementable precision oncology tools. Conclusions and Clinical Implications: The RINH algorithm achieves superior predictive performance for early mCRPC progression using exclusively clinical variables, representing a significant advance toward implementable risk stratification. However, low reliability scores in external validation underscore that excellent performance metrics alone do not guarantee stability. Before clinical deployment, validation in substantially larger cohorts with higher progression events is essential. If validated, this model could enable personalized, risk‐adapted therapeutic strategies, refining patient selection for treatment intensification or de‐escalation.

  • Towards Precision Oncology: A New Predictive Machine Learning Model for Early Progression to Castration Resistant Prostate Cancer

    by Miguel Ángel Gómez‐Luque, Paula Rodríguez‐Marcos, Rubén Campanario‐Pérez, Antonio Medina‐González, Alejandro Cárdenas‐Fernández, Walter Orlandi‐Oliveira, Manuel Ruibal‐Moldes

    Background and Objective: Metastatic castration‐resistant prostate cancer (mCRPC) is an aggressive, lethal state of prostate cancer, for which early progression is an indicator of poor prognosis. The ability to predict this progression is of paramount clinical importance for guiding personalized treatment strategies. We aimed to develop and validate a novel machine learning (ML) model to predict early progression (≤ 12 months) to mCRPC and compare its performance against standard ML algorithms. Methods: This was a retrospective analysis of 172 patients with mHSPC from the publicly available MSK‐IMPACT cohort. Inclusion criteria specified patients with mHSPC who had undergone genomic profiling and progressed to mCRPC during follow‐up. Patients with incomplete data were excluded. We collected 11 clinical, pathological, and genomic variables. The primary outcome was early progression (≤ 12 months) to mCRPC. Model performance was evaluated using a stratified fivefold cross‐validation, with AUC as the primary metric. Key Findings and Limitations: A novel Rivality Index (RINH)‐based model, adapted from chemoinformatics, demonstrated significantly superior predictive performance (AUC: 0.86) compared to a panel of standard ML algorithms, none of which exceeded an AUC of 0.67. The model achieved an accuracy of 0.74, a sensitivity of 0.70, and a specificity of 0.77. Key limitations include the retrospective design and use of a single‐institution data set. Conclusions and Clinical Implications: This novel RINH model offers a robust tool for risk stratification in mHSPC patients, capable of personalizing therapeutic strategies. However, external validation in multi‐center, prospective cohorts is an essential next step before its consideration as a clinical decision support tool.